（1）In January 2024, Tianjin Pharmaceutical Holdings Co. Ltd. and Guangdong Maijinjia Biotechnologies Co., Ltd. signed a strategic cooperation agreement, Purpose of cooperation will give full play to the resource advantages of both sides in new drug research and development innovation technology, industry, and capital, and jointly build a new technology platform for key core technology research and transformation of scientific and technological achievements.

（2）In October 2021, Maijinjia Biotechnologies Co. LTD and Ranger Biotechnologies and Servier have entered into a Research Collaboration to develop a novel therapy for treating proteinopathies in rare neurodegenerative diseases.In February 2023, the partners were changed to Guangdong Maijinjia Biotechnology Co., Ltd., MJJ Biotech A/S from Denmark, and Servier from France.